Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
We can see a decrease in the price for Rhythm Pharmaceuticals. Compared to yesterday it has lost -€1.000 (-1.030%).
With 37 Buy predictions and 1 Sell predictions Rhythm Pharmaceuticals is one of the favorites of our community.
As a result the target price of 117 € shows a positive potential of 21.24% compared to the current price of 96.5 € for Rhythm Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Rhythm Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -1.030% | 7.065% | 3.684% | 26.282% | 5.348% | 303.689% | 764.035% |
| Heron Therapeutics Inc. | 6.620% | -36.899% | -25.120% | -74.449% | -74.794% | -81.154% | -97.132% |
| Evolus Inc | 1.430% | 22.760% | 11.689% | 29.317% | 18.165% | -27.640% | -28.840% |
| Champions Oncology Inc | - | -4.803% | -12.450% | -14.510% | -24.828% | -20.727% | -50.734% |
Comments
Rhythm Pharmaceuticals (RYTM) had its price target raised by JPMorgan Chase & Co. from $145.00 to $146.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target raised by Citigroup Inc. from $142.00 to $143.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target raised by Royal Bank Of Canada from $141.00 to $155.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat